Chapter Three Recombinant Lipoproteins as Novel Vaccines with Intrinsic Adjuvant

Publication date: 2015 Source:Advances in Protein Chemistry and Structural Biology, Volume 99 Author(s): Pele Chong , Jui-Hsin Huang , Chih-Hsiang Leng , Shih-Jen Liu , Hsin-Wei Chen A core platform technology for high production of recombinant lipoproteins with built-in immunostimulator for novel subunit vaccine development has been established. This platform technology has the following advantages: (1) easily convert antigen into lipidated recombinant protein using a fusion sequence containing lipobox and express high level (50–150mg/L) in Escherichia coli; (2) a robust high-yield up- and downstream bioprocess for lipoprotein production is successfully developed to devoid endotoxin contamination; (3) the lipid moiety of recombinant lipoproteins, which is identical to that of bacterial lipoproteins is recognized as danger signals by the immune system (Toll-like receptor 2 agonist), so both innate and adaptive immune responses can be induced by lipoproteins; and (4) successfully demonstrate the feasibility and safety of this core platform technology in meningococcal group B subunit vaccine, dengue subunit vaccine, novel subunit vaccine against Clostridium difficile-associated diseases, and HPV-based immunotherapeutic vaccines in animal model studies.
Source: Advances in Protein Chemistry and Structural Biology - Category: Biochemistry Source Type: research